KALV KalVista Pharmaceuticals, Inc.
USHealthcareAs of 2026-06-10 16:00
Why KALV matters now
KalVista Pharmaceuticals, Inc. (KALV) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.00 with +0.00% on the session and $1.44B in market capitalization; recent performance reads 1-month +0.86% and YTD +67.18%.
The latest financial table shown here is Q3 2026, with revenue of $59.9M, net income of $-5.4M, and EPS of $-0.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.9%.
The latest indexable market news headline is "Chiesi Group Completes Acquisition of KalVista Pharmaceuticals" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $27.00; recent insider activity includes Piekos Brian filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-503.31
P/S
12.40
EV/EBITDA
-12.74
DCF Value
$47.94
FCF Yield
-3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.0%
Operating Margin
-120.8%
Net Margin
-119.4%
ROE
-1057.4%
ROA
-41.3%
ROIC
-46.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $59.9M | $-5.4M | $-0.11 |
| Q3 2026 | $59.9M | $-5.4M | $-0.11 |
| Q4 2026 | $40.9M | $-23.5M | $-1.08 |
| Q3 2025 | $59.9M | $-5.4M | $-0.11 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$28.67
Target (Median)
$27.00
Target Range
$27.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.11
KalVista Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. These inhibitors aim to address diseases with significant unmet medical needs. The company's core therapeutic strategy centers on its pipeline of small molecule plasma kallikrein inhibitors. These are specifically engineered to combat debilitating conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME), with several formulated as oral treatments. Key products in their portfolio include: KVD001, a plasma kallikrein inhibitor that has successfully concluded a Phase II clinical trial for the treatment of DME. Sebetralstat, which is currently advancing into the Phase 3 KONFIDENT trial, poised to become an oral, on-demand therapeutic option for acute HAE attacks. KVD824, another oral candidate in development for the management of HAE. A Factor XIIa oral inhibitor program, which is in its preclinical stage, targeting a specific enzyme implicated in HAE. The company's main offices are located in Cambridge, Massachusetts.